Morgan Stanley’s Aptevo Therapeutics APVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Hold
0
-$4 8101
2025
Q1
Sell
-11
Closed -$13.9K 8037
2024
Q4
$16.9K Buy
+11
New +$31.6K ﹤0.01% 6622
2024
Q3
Hold
0
7688
2024
Q2
Hold
0
7449
2024
Q1
Hold
0
7180
2023
Q4
Hold
0
7036
2023
Q3
Hold
0
6987
2023
Q2
Hold
0
6636
2023
Q1
Hold
0
6581
2022
Q4
Hold
0
6560
2022
Q3
Hold
0
6347
2022
Q2
Hold
0
6387
2022
Q1
Hold
0
5696
2021
Q4
Hold
0
5162
2021
Q3
Hold
0
6085
2021
Q2
Hold
0
6052
2021
Q1
Hold
0
6026
2020
Q4
Hold
0
5837
2020
Q3
Hold
0
6503
2020
Q2
Hold
0
5542
2020
Q1
Hold
0
6446
2019
Q4
Hold
0
6364
2019
Q3
Hold
0
6466
2019
Q2
Hold
0
6632
2019
Q1
Hold
0
6584
2018
Q4
Hold
0
6477
2018
Q3
Hold
0
6117
2018
Q2
Hold
0
5609
2018
Q1
Hold
0
5572
2017
Q4
Hold
0
5595
2017
Q3
Hold
0
5443
2017
Q2
Hold
0
5219
2017
Q1
Hold
0
5220
2016
Q4
Hold
0
4984
2016
Q3
Hold
0
4338

Other funds holding APVO

Morgan Stanley's APVO Position: Q2 2025 in Review

Morgan Stanley held its Aptevo Therapeutics (APVO) position steady in Q2 2025 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #8101.

Morgan Stanley first reported a position in APVO in Q4 2024 and has held it in 1 quarter since. The position peaked at $16.9K in Q4 2024. 4 funds tracked by Wall St. Rank hold APVO as of Q2 2025.

  • Morgan Stanley held 0 shares of Aptevo Therapeutics worth $0 as of Q2 2025.
  • Morgan Stanley left its Aptevo Therapeutics share count unchanged in Q2 2025.
  • Aptevo Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2025, its #8101 holding.
  • Morgan Stanley first reported a position in Aptevo Therapeutics in Q4 2024 and has held it in 1 quarter since.
  • Morgan Stanley's Aptevo Therapeutics position peaked at $16.9K in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q2 2025.

Based on Morgan Stanley's 13F filing for Q2 2025, filed 15 Aug 2025.